Moderna, Inc. (MRNA)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Why Is Moderna Stock Trading Lower On Wednesday?
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines.
Moderna's stock falls after data shows biotech's RSV vaccine trails rivals after 18 months
Moderna Inc.'s stock fell 6.4% Wednesday, after the company said that its respiratory syncytial virus, or RSV, shot showed 50% efficacy in preventing the illness after 18 months.
Moderna says its RSV shot is 50% effective across a second season
Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Moderna (MRNA) closed at $137.60 in the latest trading session, marking a +0.44% move from the prior day.
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRNA.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors
Moderna (MRNA) concluded the recent trading session at $137.90, signifying a -1.52% move from its prior day's close.
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRNA.
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. NASDAQ: MNRA made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA (mRNA) technology for the development of innovative treatments.
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRNA.
Moderna Just Gave Investors Another Reason to Buy the Stock
Moderna's combination vaccine delivered positive news from the clinic. It is yet another win for Moderna's innovative mRNA-based approach.
